Autoimmune Collaboration and Licensing Deals 2016-2026
1,066 autoimmune partnering deals | Financial benchmarks | Leading dealmakers and prospective partners | Therapeutic target analysis | Contract intelligence | Comprehensive deal directory
Autoimmune Collaboration and Licensing Deals 2016–2026
Understand the autoimmune partnering landscape using intelligence from 1,066 real-world collaboration and licensing deals.
Autoimmune Collaboration and Licensing Deals 2016–2026 provides comprehensive intelligence on 1,066 partnering deals involving autoimmune assets, technologies and development programs.
Autoimmune disease represents a broad and active area of life sciences partnering, encompassing multiple therapeutic targets, development stages, technologies and deal structures.
The report brings this activity together in one resource, enabling users to understand who is partnering, what is attracting deal activity, how transactions are structured, what financial terms have been disclosed and how partnering activity differs across autoimmune targets and technologies.
Rather than simply providing a list of transactions, the report combines market-wide deal analysis with detailed financial benchmarking, leading dealmaker intelligence, individual transaction records and access to publicly available contract documents where available.
It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in autoimmune partnering.
Understand the autoimmune partnering landscape
The report analyzes autoimmune dealmaking from 2016 to 2026, including:
-
Trends in autoimmune partnering activity by year
-
Deal activity by deal type
-
Industry sector
-
Stage of development at the time of partnering
-
Technology type
-
Autoimmune therapeutic target
-
Most active autoimmune dealmakers
-
Leading deals by disclosed value
-
How autoimmune partnering activity is evolving
This enables users to understand where activity is concentrated and identify the companies, technologies, development stages and therapeutic targets attracting partnering interest.
Benchmark autoimmune deal financials
The economics of autoimmune deals can vary significantly according to the asset, development stage, technology, rights granted and overall structure of the transaction.
The report provides dedicated analysis of disclosed financial terms, including:
-
Headline deal values
-
Upfront payments
-
Milestone payments
-
Royalty rates
Individual transactions can then be investigated in greater depth to understand the context behind the disclosed economics.
This provides users with real-world reference points when preparing internal benchmarks, evaluating opportunities or entering partnering discussions.
Financial benchmarks are most valuable when considered alongside the structure and circumstances of comparable deals rather than as standalone averages, and the report provides the wider transaction intelligence needed to establish that context.
Identify leading autoimmune dealmakers and prospective partners
The report identifies the most active companies in autoimmune dealmaking and provides extensive transaction histories that enable users to investigate their partnering activity.
This can help users identify:
-
Companies actively seeking autoimmune opportunities
-
Potential licensing and collaboration partners
-
Organizations repeatedly partnering in particular therapeutic areas
-
Companies active at relevant stages of development
-
Dealmakers showing interest in specific technologies or approaches
-
Competitors pursuing similar external innovation strategies
For companies seeking to partner an autoimmune asset or technology, previous deal activity can provide valuable evidence of which organizations have demonstrated a genuine appetite for comparable opportunities.
Compare deals across therapeutic targets
Autoimmune is not a single homogeneous partnering market.
The report provides analysis by autoimmune therapeutic target, enabling users to investigate differences in partnering activity across individual areas of autoimmune disease and identify transactions most relevant to a particular program or strategic interest.
This helps users move beyond broad autoimmune benchmarks and focus on the subset of transactions most relevant to their own opportunity.
Understand how autoimmune agreements are structured
The report includes collaboration, licensing and other partnering transactions, enabling users to examine how companies have structured relationships around autoimmune assets and technologies.
Depending on the transaction and available disclosure, users can investigate areas including:
-
Rights granted and retained
-
Research and development responsibilities
-
Licensing rights
-
Exclusivity
-
Geographic rights
-
Intellectual property
-
Development and regulatory responsibilities
-
Commercialization rights
-
Financial consideration
-
Milestones and royalties
-
Governance
-
Term and termination provisions
These real-world examples provide useful reference points when considering the appropriate structure for a new autoimmune partnership.
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected autoimmune transactions.
These agreements can reveal substantially more detail than headline announcements alone, helping users understand how companies have documented areas such as:
-
Scope of rights
-
Development obligations
-
Intellectual property
-
Exclusivity
-
Financial terms
-
Milestone triggers
-
Royalty provisions
-
Commercialization rights
-
Termination and other negotiated provisions
For teams preparing or negotiating an autoimmune collaboration or licensing transaction, access to real agreement language provides valuable insight into how comparable deals have been structured in practice.
Comprehensive autoimmune deal directory
The report includes a comprehensive directory of 1,066 autoimmune collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.
Deals can be reviewed by:
-
Company
-
Technology type
-
Therapeutic target
-
Contract availability
Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
Who should use this report?
Business Development and Licensing teams
Identify comparable autoimmune transactions, prospective partners and relevant deal structures.
Search and Evaluation teams
Understand which companies are actively seeking opportunities across particular autoimmune targets, technologies and stages of development.
Biotechnology Companies Seeking Partners
Identify organizations with demonstrated interest in comparable autoimmune assets and technologies.
Corporate and R&D Strategy teams
Understand how competitors and potential partners are building autoimmune pipelines through external innovation.
Competitive and Market Intelligence teams
Track activity by company, development stage, technology and therapeutic target to understand evolving partnering priorities.
Legal and Transaction teams
Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
Turn market-wide autoimmune intelligence into company-specific insight
For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
The briefing applies the underlying autoimmune deal intelligence to the customer's own asset, technology, target or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.
Key Benefits
✔ Benchmark against 1,066 autoimmune partnering deals – Access a substantial body of real-world collaboration and licensing activity to identify relevant precedents and comparable transactions.
✔ Benchmark autoimmune deal financials – Analyze disclosed headline values, upfront payments, milestones and royalty rates and investigate the individual transactions behind the benchmarks.
✔ Identify prospective partners and leading dealmakers – Discover companies with demonstrated interest in autoimmune assets, technologies, therapeutic targets and relevant stages of development.
✔ Compare activity across the autoimmune landscape – Analyze dealmaking by therapeutic target, development stage, technology type, deal type, industry sector and company.
✔ Find the most relevant comparable transactions – Move beyond broad market averages to identify deals involving similar targets, technologies, development stages and partnering structures.
✔ Understand how autoimmune deals are structured – Examine licensing rights, development responsibilities, exclusivity, IP, commercialization rights, milestones, royalties and other important transaction provisions.
✔ Learn from real contract documents – Where publicly available, review underlying agreements to understand how rights, obligations, financial terms and other negotiated provisions have been documented.
✔ Apply the intelligence to your own autoimmune opportunity – Qualifying customers may also be eligible for a Customized Executive Partnering Briefing focused on their own asset, target, technology, prospective partners or transaction objectives.
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in autoimmune dealmaking
2.1. Introduction
2.2. Autoimmune deals over the years
2.3. Autoimmune deals by deal type
2.4. Autoimmune deals by industry sector
2.5. Autoimmune deals by stage of development
2.6. Autoimmune deals by technology type
Chapter 3 – Financial deal terms for autoimmune deals
3.1. Introduction
3.2. Disclosed financials terms for autoimmune deals
3.3. Autoimmune deal headline values
3.4. Autoimmune deal upfront payments
3.5. Autoimmune deal milestone payments
3.6. Autoimmune deal royalty rates
Chapter 4 – Leading autoimmune dealmakers and deals
4.1. Introduction
4.2. Most active in autoimmune dealmaking
4.3. List of most active dealmakers in autoimmune
4.4. Top autoimmune deals by value
Chapter 5 – Autoimmune deal contract document directory
5.1. Introduction
5.2. Autoimmune partnering deals where contract document available
Chapter 6 – Autoimmune dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by autoimmune therapeutic target
Deal Directory
Deal Directory – Autoimmune deals by company A-Z
Deal Directory – Autoimmune deals by technology type
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Autoimmune deals since 2016
Figure 2: Autoimmune deals by deal type since 2016
Figure 3: Autoimmune deals by industry sector since 2016
Figure 4: Autoimmune deals by stage of development since 2016
Figure 5: Autoimmune deals by technology type since 2016
Figure 6: Autoimmune deals with a headline value
Figure 7: Autoimmune deals with upfront payment values
Figure 8: Autoimmune deals with milestone payment
Figure 9: Autoimmune deals with royalty rates
Figure 10: Active autoimmune dealmaking activity since 2016
Figure 11: Top autoimmune deals by value since 2016
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
All card payments are processed by Evalon.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
About Current Partnering
A definitive, evidence-based approach to dealmaking intelligence
Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.
Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.
All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.
Our methodology
Built on a continuously updated proprietary database
All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.
Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.
Comprehensive and verifiable data sourcing
Deal data is sourced from publicly available industry disclosures, including:
- Company press releases and announcements
- SEC filings and equivalent regulatory disclosures
- Company and investor presentations
- Conference materials and company websites
All sources are captured and referenced, enabling full transparency and user verification.
Broad coverage across deal types and structures
Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:
- Licensing and co-development
- Research and collaborative R&D
- Manufacturing, supply, and distribution
- Commercialisation and co-promotion
- Equity investments, joint ventures, and asset transactions
- Options, royalties, and financing agreements
This breadth ensures a complete view of how partnerships are structured across the life sciences sector.
Structured, standardised analysis
Every deal is analysed using a consistent framework, capturing (where disclosed):
- Financial terms — including upfront payments, milestones, and royalties
- Rights allocation — development, manufacturing, and commercialization responsibilities
- Deal structure — exclusivity, territorial scope, and agreement type
- Contractual provisions — clauses defining risk, control, and value-sharing
Each deal record is fully categorised, including data fields such as:
- Therapy area and technology type
- Stage of development
- Asset type and deal components
- Geographic scope and exclusivity
- Source documentation, including press releases and SEC filings
Financial normalisation for comparability
All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.
Contract-level insight
Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.
This enables users to understand:
- How financial mechanisms are defined and triggered
- How responsibilities are operationalised between parties
- How flexibility, risk, and control are allocated within agreements
Designed for real-world application
Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:
- Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
- Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
- Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight
Common use cases include:
- Benchmarking comparable transactions
- Supporting valuation and deal structuring
- Preparing for negotiations
- Evaluating potential partners
- Informing internal strategy with real-world evidence
A trusted industry reference
With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.
By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.
